Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

NCT04945148 is registered in ClinicalTrials.gov with Hopital Foch as lead sponsor.

NCT NCT04945148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04945148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Lead sponsor
Hopital Foch
Phase
Phase 2
Overall status
Recruiting
Start date
May 10, 2024
Completion date
May 31, 2028
Enrollment
640 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh-wildtype